Bausch Health Cos Inc. (NYSE:BHC) Receives $8.00 Average Price Target from Brokerages

Shares of Bausch Health Cos Inc. (NYSE:BHC) have been given a consensus rating of “Reduce” by the five brokerages that are currently covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating and four have assigned a hold rating to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $8.00.

A number of research firms have recently commented on BHC. Barclays cut their target price on Bausch Health Cos from $8.00 to $7.00 and set an “equal weight” rating on the stock in a research note on Wednesday, February 25th. Weiss Ratings cut Bausch Health Cos from a “sell (d)” rating to a “sell (d-)” rating in a research report on Monday, May 4th. Royal Bank Of Canada dropped their price objective on Bausch Health Cos from $10.00 to $9.00 and set a “sector perform” rating on the stock in a research report on Monday, April 27th. Raymond James Financial reaffirmed a “market perform” rating on shares of Bausch Health Cos in a research report on Monday, January 26th. Finally, Wall Street Zen cut Bausch Health Cos from a “strong-buy” rating to a “buy” rating in a research report on Sunday, February 15th.

Key Headlines Impacting Bausch Health Cos

Here are the key news stories impacting Bausch Health Cos this week:

• Positive Sentiment: Bausch Health announced results from its 2026 Annual Meeting of Shareholders, saying all 10 director nominees were elected, including new director Eiry W. Roberts, M.D. The vote suggests continued shareholder support and adds a board member with pharmaceutical leadership experience. Bausch Health Announces 2026 Annual Meeting of Shareholder Results
• Positive Sentiment: Zacks Research nudged up its FY2026 EPS estimate for Bausch Health to $3.93 from $3.92, which is a small sign of improving near-term earnings expectations. Zacks Research FY2026 estimate update
• Neutral Sentiment: The company presented at the RBC Capital Markets Global Healthcare Conference and the Barclays Leveraged Finance Conference. These events can help investor visibility, but no major new operating update was provided in the available transcript headlines. RBC Capital Markets Global Healthcare Conference Transcript Barclays Leveraged Finance Conference Transcript
• Neutral Sentiment: Brokerage commentary reported a $8.00 price target, which is supportive but not a direct catalyst on its own. Brokerages Set Bausch Health Cos Inc. Target Price at $8.00
• Negative Sentiment: Zacks Research trimmed several longer-term earnings forecasts for Bausch Health, including FY2027, FY2028, Q2 2027, Q3 2026, and Q1 2028, signaling softer growth expectations farther out. Zacks Research earnings estimate changes
• Negative Sentiment: Director Frank D. Lee sold 24,456 shares in a pre-arranged Rule 10b5-1 transaction. While routine, insider selling can still weigh on sentiment for BHC. SEC Form 4 insider sale filing

Insider Activity at Bausch Health Cos

In related news, Director Frank D. Lee sold 24,456 shares of the stock in a transaction on Tuesday, May 19th. The stock was sold at an average price of $5.43, for a total transaction of $132,796.08. Following the sale, the director directly owned 49,339 shares of the company’s stock, valued at $267,910.77. This trade represents a 33.14% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 20.67% of the stock is owned by company insiders.

Institutional Investors Weigh In On Bausch Health Cos

Several institutional investors have recently modified their holdings of the business. Tidal Investments LLC boosted its position in shares of Bausch Health Cos by 2.6% during the second quarter. Tidal Investments LLC now owns 50,131 shares of the company’s stock valued at $334,000 after buying an additional 1,276 shares during the last quarter. Commonwealth Equity Services LLC boosted its position in shares of Bausch Health Cos by 14.8% during the fourth quarter. Commonwealth Equity Services LLC now owns 14,067 shares of the company’s stock valued at $98,000 after buying an additional 1,812 shares during the last quarter. Pictet Asset Management Holding SA boosted its position in Bausch Health Cos by 4.1% in the first quarter. Pictet Asset Management Holding SA now owns 54,169 shares of the company’s stock worth $292,000 after purchasing an additional 2,114 shares during the last quarter. CANADA LIFE ASSURANCE Co boosted its position in Bausch Health Cos by 2.5% in the second quarter. CANADA LIFE ASSURANCE Co now owns 104,156 shares of the company’s stock worth $690,000 after purchasing an additional 2,552 shares during the last quarter. Finally, Russell Investments Group Ltd. boosted its position in Bausch Health Cos by 65.9% in the second quarter. Russell Investments Group Ltd. now owns 7,819 shares of the company’s stock worth $51,000 after purchasing an additional 3,106 shares during the last quarter. 78.65% of the stock is owned by hedge funds and other institutional investors.

Bausch Health Cos Trading Up 3.5%

NYSE BHC opened at $5.51 on Friday. Bausch Health Cos has a 12 month low of $4.41 and a 12 month high of $8.69. The stock has a market cap of $2.06 billion, a P/E ratio of -1.70 and a beta of 0.42. The stock’s fifty day moving average price is $5.42 and its 200-day moving average price is $6.13. The company has a current ratio of 1.32, a quick ratio of 0.97 and a debt-to-equity ratio of 54.68.

Bausch Health Cos (NYSE:BHC) last released its earnings results on Wednesday, April 29th. The company reported $0.78 EPS for the quarter, missing analysts’ consensus estimates of $0.81 by ($0.03). Bausch Health Cos had a negative return on equity of 2,922.77% and a negative net margin of 11.47%.The company had revenue of $2.46 billion during the quarter, compared to analysts’ expectations of $2.37 billion. As a group, equities analysts forecast that Bausch Health Cos will post 4.08 EPS for the current fiscal year.

About Bausch Health Cos

Bausch Health Cos Inc, formerly known as Valeant Pharmaceuticals International, is a global specialty pharmaceutical company headquartered in Laval, Quebec, Canada. The company operates through two primary segments: Ophthalmology, led by its Bausch + Lomb franchise, and Diversified Brands, which encompasses prescription dermatology, gastrointestinal, neurology and branded pharmaceutical products. Bausch Health develops, manufactures and markets a range of therapeutic and over-the-counter offerings designed to address conditions such as cataracts, dry eye, glaucoma, acne, rosacea, migraine and gastrointestinal disorders.

The Ophthalmology segment under the Bausch + Lomb name provides products for eye health, including prescription drops, contact lens care solutions, intraocular lenses, surgical instruments and diagnostic devices.